Modified chemotherapy combo for relapsed large b-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study compares two chemotherapy regimens for people with diffuse large B-cell lymphoma that has returned or not responded to earlier treatment. The goal is to see if a modified version is as effective with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has either come back or did not go away with previous treatment.
- You are at least 18 years old.
- You have had at least one prior treatment for your lymphoma.
- You are in reasonably good health (able to care for yourself and do light activities).
- Your blood counts, kidneys, and liver are functioning well enough (e.g., certain minimum levels of white blood cells and platelets).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different combinations of chemotherapy drugs for people whose large B-cell lymphoma has come back more than a year after treatment. The goal is to see which regimen is more effective and safer.
This study tests a new drug called SCTB35 combined with two common chemotherapy drugs (gemcitabine and oxaliplatin) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatment. The goal is to see if this combination is safe and helps shrink the cancer.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.